stoxline Quote Chart Rank Option Currency Glossary
MediciNova, Inc. (MNOV)
1.43  0.04 (2.88%)    07-12 13:32
Open: 1.44
High: 1.46
Volume: 5,319
Pre. Close: 1.39
Low: 1.38
Market Cap: 70(M)
Technical analysis
2024-07-12 1:22:17 PM
Short term     
Mid term     
Targets 6-month :  1.71 1-year :  2
Resists First :  1.47 Second :  1.71
Pivot price 1.4
Supports First :  1.35 Second :  1.27
MAs MA(5) :  1.38 MA(20) :  1.38
MA(100) :  1.39 MA(250) :  1.7
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  57.8 D(3) :  54.9
RSI RSI(14): 52
52-week High :  2.57 Low :  1.25
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MNOV ] has closed above bottom band by 42.4%. Bollinger Bands are 57.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.41 - 1.42 1.42 - 1.42
Low: 1.34 - 1.34 1.34 - 1.35
Close: 1.38 - 1.39 1.39 - 1.4
Company Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Headline News

Wed, 10 Jul 2024
MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200-Day Moving Average of $1.41 - MarketBeat

Wed, 10 Jul 2024
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at - MarketBeat

Wed, 10 Jul 2024
MediciNova (NASDAQ:MNOV) Stock Passes Above Two Hundred Day Moving Average of $1.41 - Defense World

Wed, 10 Jul 2024 Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World

Tue, 02 Jul 2024 Begins Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat

Sat, 29 Jun 2024
Short Interest in MediciNova, Inc. (NASDAQ:MNOV) Drops By 18.4% - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 49 (M)
Held by Insiders 4.208e+007 (%)
Held by Institutions 2.9 (%)
Shares Short 159 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.005e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 7.3 %
Return on Equity (ttm) -9.4 %
Qtrly Rev. Growth 1e+006 %
Gross Profit (p.s.) 0
Sales Per Share -18.31
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -0.4
Price to Book value 0
Price to Sales -0.08
Price to Cash Flow 0.82
Stock Dividends
Dividend 0
Forward Dividend 110730
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android